Oruka Therapeutics, Inc. ORKA Issuance of warrants to purchase common stock
Issuance of warrants to purchase common stock at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s issuance of warrants to purchase common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s issuance of warrants to purchase common stock?
- Oruka Therapeutics, Inc. (ORKA) reported issuance of warrants to purchase common stock of $2.52M in Q4 2025.
- How has Oruka Therapeutics, Inc.'s issuance of warrants to purchase common stock changed year-over-year?
- Oruka Therapeutics, Inc.'s issuance of warrants to purchase common stock decreased by 75.7% year-over-year, from $10.36M to $2.52M.
- What does issuance of warrants to purchase common stock mean?
- Reflects the accounting adjustments made to additional paid-in capital resulting from the issuance of warrants to purchase common stock. This captures the non-cash impact of equity-linked instruments on the company's capital structure. It helps investors understand the potential future dilution and the cost of financing activities.